<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>cytotoxicity improvement &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/cytotoxicity-improvement/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sun, 16 Nov 2025 18:28:44 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>cytotoxicity improvement &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Enhanced CAR-T Cytotoxicity via IDR-Induced Condensation</title>
		<link>https://bioengineer.org/enhanced-car-t-cytotoxicity-via-idr-induced-condensation/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 16 Nov 2025 18:28:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CAR-T cell engineering]]></category>
		<category><![CDATA[CAR-T therapy enhancement]]></category>
		<category><![CDATA[cytotoxicity improvement]]></category>
		<category><![CDATA[IDR-induced condensation]]></category>
		<category><![CDATA[low-antigen cancer treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/enhanced-car-t-cytotoxicity-via-idr-induced-condensation/</guid>

					<description><![CDATA[In a groundbreaking study published in Nature Chemical Biology, researchers elucidate the transformative potential of intracellular delivery of multivalent binding agents, specifically Intrinsically Disordered Regions (IDRs), in enhancing the efficacy of Chimeric Antigen Receptor T-cells, commonly known as CAR-Ts. This innovative approach addresses a significant challenge in the therapeutic landscape: the treatment of low-antigen tumors, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">297589</post-id>	</item>
	</channel>
</rss>
